Chemotherapy-induced cardiotoxicity and mitigation

Dietary nitrate and nitrite protect against doxorubicin-induced cardiac fibrosis and oxidative protein damage in tumor-bearing mice

This study shows that dietary nitrate and nitrite reduce cardiac fibrosis and oxidative damage in tumor-bearing mice treated with doxorubicin without affecting tumor response.

AICAr inhibition of cardiomyocyte autophagy promotes p62-dependent NRF2 expression and protection against doxorubicin toxicity

This study shows that AICAr protects cardiomyocytes from doxorubicin toxicity by inhibiting autophagy, increasing p62, and enhancing NRF2 activity through ADK-dependent mechanisms.

CARP Protects Against Doxorubicin-induced Cardiotoxicity through NRF1-driven Mitochondrial Homeostasis

This study shows CARP protects against doxorubicin-induced cardiotoxicity by maintaining mitochondrial homeostasis through NRF1 signaling.

Anthracyclines induce global changes in cardiomyocyte chromatin accessibility that overlap with cardiovascular disease loci

This study shows anthracyclines alter chromatin accessibility in cardiomyocytes, overlapping with cardiovascular disease risk loci.

A new 1,4-Dihydropyridine-Based L-/T-Type Calcium Channel Inhibitor, HM12, Provides in Vivo and in silico Cardioprotective Effects in Doxorubicin-Treated Rats

This study evaluates HM12, a calcium channel inhibitor, for cardioprotective effects against doxorubicin toxicity in rats, showing improved antioxidant status and reduced inflammation.

ATF4 alleviates doxorubicin-induced cardiomyopathy through H2S-mediated antioxidation

This study shows ATF4 protects against doxorubicin-induced cardiomyopathy by enhancing H2S-mediated antioxidation through upregulation of CSE.

KICDB: A Causality-Oriented Multi-Omics Database for Kinase Inhibitor-Induced Cardiotoxicity

The paper introduces KICDB, a database that integrates transcriptomic and causal inference data to explore the mechanisms of kinase inhibitor-induced cardiotoxicity.

Advanced Cardiac Organoid Model for Studying Doxorubicin-Induced Cardiotoxicity

This study develops an advanced cardiac organoid model with fibroblast-driven ECM self-secretion to better mimic adult cardiac physiology and assess doxorubicin-induced cardiotoxicity.

Mx1-Cre-mediated Rac1 knockout confers multiple protective effects against anthracycline-induced acute normal tissue injury

This study shows that Rac1 deletion reduces anthracycline-induced organ damage in mice, with effects varying by organ and drug type.

Differential responses of murine embryonic stem cells (mESC) and their endothelial progeny to doxorubicin and pharmacological inhibitors of DNA repair and DNA damage response

This study compares the response of murine embryonic stem cells and their endothelial progeny to doxorubicin and DNA repair inhibitors, finding differential susceptibility and functional impairments in differentiated cells.

Preconditioning of human iPSCs with doxorubicin causes genome-wide transcriptional reprogramming in iPSC-derived cardiomyocytes linked to mitochondrial dysfunction and impaired cardiac regeneration

This study shows that low-dose doxorubicin treatment of human iPSCs causes mitochondrial dysfunction and transcriptional changes that impair cardiac regeneration in derived cardiomyocytes.

SERUM AND PLASMA SPHINGOLIPIDS AS BIOMARKERS OFANTHRACYCLINE-INDUCED CARDIOTOXICITY

This study identifies serum and plasma sphingolipids as potential biomarkers for anthracycline-induced cardiotoxicity, showing correlations with cardiac outcomes during and after therapy.

Transcriptomic insights into early diagnosis of doxorubicin-induced cardiotoxicity in a rat model

This study identifies transcriptomic changes in a rat model of doxorubicin-induced cardiotoxicity, revealing metabolic dysregulation and circadian rhythm disruption that may inform early diagnostic biomarkers.

A Critical Role for Neutral Sphingomyelinase-2 in Doxorubicin-induced Cardiotoxicity

This study identifies nSMase2 as a critical mediator of Doxorubicin-induced cardiotoxicity and shows its loss protects against cardiac damage.

Intensive Chemotherapy Induces Cardiotoxicity via Reverse Electron Transport

This study shows malonate prevents chemotherapy-induced cardiotoxicity by inhibiting mitochondrial reverse electron transport, preserves cardiac function, and sensitizes AML cells to intensive chemotherapy.

Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography

This study evaluates anthracycline-induced arterial injury in non-human primates and lymphoma patients using histopathology and PET/CT, finding increased fibrosis in primates but no inflammation in patients.

Multiscale mapping of transcriptomic signatures for cardiotoxic drugs

The paper identifies cardiotoxic drug signatures using bulk transcriptomics and integrates them with genomic and single-cell data to predict toxicity mechanisms.

Identification of Candidate Diagnostic gene CDC25C for Trametinib-induced Cardiotoxicity by Integrating Bioinformatics and Machine Learning

Inhibition of Cyp1a Protects Mice against Anthracycline Cardiomyopathy

This study shows that inhibiting Cyp1a protects mice from anthracycline-induced cardiomyopathy by reducing cardiac dysfunction and altering gene expression related to mitophagy and inflammation.

Anthracycline-induced cardiotoxicity associates with a shared gene expression response signature to TOP2-inhibiting breast cancer drugs in cardiomyocytes

The paper investigates the shared gene expression response to TOP2-inhibiting breast cancer drugs in cardiomyocytes and identifies genetic factors associated with inter-individual variation in cardiotoxicity.

Identification Drug Targets for Oxaliplatin-Induced Cardiotoxicity without affecting cancer treatment through Inter Variability Cross-Correlation Analysis (IVCCA)

The paper introduces IVCCA, a bioinformatics tool to identify drug targets for oxaliplatin-induced cardiotoxicity without affecting cancer treatment, finding new pathways like energy metabolism as potential therapeutic targets.

Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk

The paper identifies genetic markers for anthracycline-induced cardiotoxicity risk by analyzing intermediate molecular phenotypes in mice and human cohorts.

Remote Ischemic Preconditioning Ameliorates Anthracycline-induced Cardiotoxicity and Preserves Mitochondrial Integrity

This study shows that remote ischemic preconditioning (RIPC) before doxorubicin injections reduces cardiotoxicity by preserving mitochondrial integrity and cardiac function in pigs.

SIRT6 as a transcriptional coactivator of GATA4 prevents doxorubicin cardiotoxicity independently of its deacylase activity

This study identifies SIRT6 as a non-enzymatic coactivator of GATA4 that protects against doxorubicin-induced cardiotoxicity by enhancing GATA4 acetylation through recruitment of Tip60.

Retinoid X receptor alpha is a spatiotemporally-specific therapeutic target for doxorubicin-induced cardiomyopathy in adult zebrafish

This study identifies RXRA as a therapeutic target for doxorubicin-induced cardiomyopathy in zebrafish by showing its endothelial-specific function and response to FDA-approved agonists.

Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes

This study identifies genetic variants influencing the transcriptomic response to doxorubicin in cardiomyocytes and links them to anthracycline-induced cardiotoxicity risk.